MetaCap

CorMedix (CRMD) vs Evolus (EOLS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Evolus (EOLS) has outperformed CorMedix (CRMD) over the past year, losing 4.8% versus a loss of 45.6%. Over five years, EOLS leads with a +14.4% price change compared with +3.9% for CRMD. Evolus is the larger company by market cap ($431.5 million vs $419.2 million), about 1.0 times the size, while CorMedix is growing revenue faster (+617.0% vs +11.6%).

On valuation, CorMedix trades at a lower forward P/E (15.1x vs 22.7x for Evolus). CorMedix converts more of its revenue into profit, with a net margin of 52.3% versus -17.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRMD-45.56%EOLS-4.82%
+40%-9%-58%
Nov 21, 20251 yearNov 20, 2026
CRMD+2.73%EOLS+2.19%
+201%+72%-57%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRMD versus EOLS key metrics
MetricCRMDEOLS
Share price$5.27$6.52
Market cap$419.16M$431.55M
1-day change+3.74%-6.86%
YTD return-54.69%-1.95%
1-year return-45.56%-4.82%
5-year return+3.94%+14.39%
P/E ratio (TTM)8.23—
Forward P/E15.0622.68
EPS (TTM)$0.64$-0.48
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$311.71M$297.18M
Revenue growth (YoY)+617.03%+11.61%
Net income (latest FY)$163.06M$-51.64M
Gross margin88.46%66.33%
Operating margin48.17%-10.99%
Net margin52.31%-17.38%
52-week high$13.02$9.31
52-week low$4.47$3.86
Distance from 52-week high-59.52%-29.97%
Analyst consensusbuystrong_buy
Avg. price target upside+161.86%+136.20%
Average volume1.44M925.77K
Shares outstanding79.54M66.19M
Employees191365
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EOLS has outperformed CRMD by 40.7 percentage points over the past year.
  • CorMedix is more profitable, keeping 52.3 cents of every revenue dollar as net income versus -17.4 cents for Evolus.
  • CorMedix grew revenue faster in its latest fiscal year (+617.03% vs +11.61%).

About CorMedix

CRMD stock →

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.

Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees

About Evolus

EOLS stock →

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.

Health Care · Biotechnology: Pharmaceutical Preparations · 365 employees

CRMD vs EOLS FAQ

Which is bigger, CorMedix or Evolus?

Evolus (EOLS) is larger, with a market capitalization of $431.55M compared with $419.16M for CorMedix (CRMD).

Which stock has performed better over the past year, CRMD or EOLS?

EOLS returned -4.82% over the past 12 months, compared with -45.56% for CRMD (price return, excluding dividends). Past performance does not predict future results.

Are CorMedix and Evolus in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons